Cardiff Oncology, Inc. (CRDF) News

Cardiff Oncology, Inc. (CRDF): $2.45

0.01 (+0.41%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add CRDF to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#322 of 347

in industry

Filter CRDF News Items

CRDF News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CRDF News From Around the Web

Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 35th Annual Piper Sandler Healthcare Conference, which is taking place at the Lotte New York Palace in New York from November 28-30, 2023.

Yahoo | November 20, 2023

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.

Yahoo | November 2, 2023

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | October 31, 2023

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading.

Yahoo | October 26, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!

William White on InvestorPlace | September 27, 2023

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive clinical data with onvansertib monotherapy and combination therapy in our ongoing trials in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC), as well as plans for a mPDAC first-line investigator-initiated trial (IIT) of the combination of onvansertib plus standard-of-care (SoC).

Yahoo | September 26, 2023

Cardiff Oncology to Present at Upcoming Investor Conferences in September

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will present at the Baird Global Healthcare Conference on September 12, 2023 and the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.

Yahoo | September 5, 2023

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

Yahoo | August 9, 2023

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced plans to advance the company's lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct its new CRDF-004 trial with study execution support from Pfizer Ignite, a new end-to-end service for biotech companies.

Yahoo | August 7, 2023

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that on July 24, 2023, non-qualified stock option awards to purchase an aggregate of 50,016 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance wi

Yahoo | July 24, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!